Clinical Trial: PD-1 + FOLFOXIRI vs CAPOX as Total Neoadjuvant Therapy for pMMR Low Rectal Cancer

U.S., Dec. 12 -- ClinicalTrials.gov registry received information related to the study (NCT07277842) titled 'PD-1 + FOLFOXIRI vs CAPOX as Total Neoadjuvant Therapy for pMMR Low Rectal Cancer' on Nov. 30.

Brief Summary: The goal of this clinical trial is to find out if adding a PD-1 antibody (serplulimab) to FOLFOXIRI chemotherapy and radiotherapy works better than CAPOX chemotherapy with radiotherapy as total neoadjuvant therapy for adults with pMMR locally advanced low rectal cancer. It will also look at the safety of these treatments and how they affect long-term outcomes such as organ preservation and survival.

The main questions it aims to answer are:

Does PD-1 antibody plus FOLFOXIRI with radiotherapy improve 3-year event-free survi...